Fly News Breaks for May 23, 2019
May 23, 2019 | 07:21 EDT
Guggenheim analyst David Westenberg initiated coverage on 10 companies in animal health, starting Zoetis with a Buy rating and $114 price target. He believes Zoetis' current "big three" of Simparica, CYTOPOINT, and Apoquel will allow it to meet near-term growth targets and thinks the company should see significant growth from new products in pain and parasiticides that are currently underappreciated.
News For ZTS From the Last 2 Days
Jul 22, 2019 | 07:56 EDT
Stifel analyst Jonathan Block said his checks indicate that a Triple combo product "is the most sought after future pharmaceutical product innovation that Veterinarians want to see" and he believes being first to market such a "Triple" can meaningfully increase Zoetis' market share in parasiticides. In addition to a Triple, Veterinarians' want for a product for feline pain, which Zoetis may introduce in 2021, noted Block, who raised his price target on Zoetis shares to $130 from $110 and keeps a Buy rating on the stock.